Join
Live feed
·
PRReleasevia Quantisnow
Miragen Therapeutics, Inc. logo

miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
MGEN· Miragen Therapeutics, Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MGEN (Miragen Therapeutics, Inc.) and more on Quantisnow.